English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -96.54%
Price change 2019 → 2020: -84.00%
Price change 2020 → 2021: -33.33%
Price change 2021 → 2022: -96.72%
Price change 2022 → 2023: -99.68%
Price change 2023 → 2024: -98.80%
Price change 2024 → 2025: 86.50%
Price change 2025 → 2026: -43.75%
Price change 2026 (year to date): -44.48%
Financial growth
Revenue CAGR (8 years): 8.75%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.07
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -6.18
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 43.82% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ALSPW.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Spineway S.A. | – | 0.07 | +9.3 % | 🔒 |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| Biosynex S.A. | – | 1.90 | +35.4 % | – |
| Valbiotis S.A. | – | 0.73 | +56.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Spineway S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 3.8 m | -15.7 m | -415.8 % | n/a |
| 2021 | 4.8 m | -1.8 m | -36.9 % | +27.0 % |
| 2022 | 8.3 m | -3.5 m | -42.2 % | +73.2 % |
| 2023 | 11.7 m | -7.3 m | -61.9 % | +41.5 % |
| 2024 | 13.3 m | -4.3 m | -32.3 % | +13.6 % |
| 2025 | 13.9 m | -2.5 m | -18.0 % | +4.0 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Spineway S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 13.9 m | 5.5 m | 1.8 m | 4.5 m | 3.5 m |
| Total Debt | 2.4 m | 1.4 m | 2.6 m | 1.8 m | 1.5 m |
| Net Debt | -11.5 m | -2.6 m | 803,000 | -2.7 m | -2.0 m |
| Equity | 20.9 m | 22.0 m | 19.1 m | 24.2 m | 23.1 m |
| Total assets | 25.6 m | 27.7 m | 26.3 m | 30.4 m | 29.5 m |
| Operating cash flow | -1.8 m | -1.6 m | -5.8 m | -3.3 m | 424,000 |
| Investments (capex) | 1.1 m | 12.3 m | 1.2 m | -3.3 m | 424,000 |
| Free cash-flow | -2.9 m | -13.9 m | -7.3 m | -3.3 m | 0 |
| Share buybacks | 0 | 0 | 199,000 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Spineway S.A. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Spineway S.A. | 3.5 m | n/a | -18.0 % |
| Nakanishi Inc. 7716.T | 1.5 bn | 51.8 | -3.0 % |
| Biophytis S.A. ALBPS.PA | 800,210 | n/a | n/a |
| DBT S.A. ALDBT.PA | 271,689 | n/a | -108.2 % |
| SpineGuard S.A. ALSGD.PA | 9.9 m | n/a | -55.0 % |
| Safilo Group S.p.A. SFL.MI | 856 m | 15.6 | 5.0 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Spineway S.A.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Stock splits
| Date | Operation |
|---|---|
| 27/02/2024 | reverse split: 1 share for 2,000 |
| 15/09/2022 | reverse split: 1 share for 40,000 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Spineway S.A.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Spineway S.A.
What is the Spineway S.A. share price?
Latest recorded price: 0.0950 EUR on 06/11/2026, for a market cap of 3.6 m USD.
What is the revenue of Spineway S.A.?
13.9 m USD for fiscal year 2025, with net income of -2.5 m USD (net margin -18.0 %).
Is Spineway S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR001400N2P2) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Spineway S.A. have?
48 full-time employees according to the latest published profile.
Who runs Spineway S.A.?
Stephane Le Roux is the company's chief executive.